Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 710

1.

Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.

Kothari S, Nelson SP, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

Curr Med Res Opin. 2009 Nov;25(11):2703-9. doi: 10.1185/03007990903307755.

PMID:
19775195
2.

Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy.

Nelson SP, Kothari S, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

J Med Econ. 2009;12(4):348-55. doi: 10.3111/13696990903378680.

PMID:
19827992
3.

Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.

Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP).

Pediatrics. 2006 May;117(5):e817-20.

PMID:
16651285
4.

A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.

Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G.

Am J Gastroenterol. 2000 Feb;95(2):395-407.

PMID:
10685741
5.

Treatment patterns and symptom control in patients with GERD: US community-based survey.

Chey WD, Mody RR, Wu EQ, Chen L, Kothari S, Persson B, Beaulieu N, Lu M.

Curr Med Res Opin. 2009 Aug;25(8):1869-78. doi: 10.1185/03007990903035745.

PMID:
19530980
6.

Development of a refractory gastro-oesophageal reflux score using an administrative claims database.

Gerson LB, Bonafede M, Princic N, Gregory C, Farr A, Balu S.

Aliment Pharmacol Ther. 2011 Sep;34(5):555-67. doi: 10.1111/j.1365-2036.2011.04755.x. Epub 2011 Jun 30.

7.

The economics of laparoscopic Nissen fundoplication.

Dire CA, Jones MP, Rulyak SJ, Kahrilas PJ.

Clin Gastroenterol Hepatol. 2003 Jul;1(4):328-32.

PMID:
15017676
8.
9.

A practice-based approach for converting from proton pump inhibitors to less costly therapy.

Lucas LM, Gerrity MS, Anderson T.

Eff Clin Pract. 2001 Nov-Dec;4(6):263-70.

PMID:
11769299
10.

Marked increase in proton pump inhibitors use in Australia.

Hollingworth S, Duncan EL, Martin JH.

Pharmacoepidemiol Drug Saf. 2010 Oct;19(10):1019-24. doi: 10.1002/pds.1969.

PMID:
20623646
11.

The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts.

Toghanian S, Wahlqvist P, Johnson DA, Bolge SC, Liljas B.

Clin Drug Investig. 2010;30(3):167-78. doi: 10.2165/11531670-000000000-00000.

PMID:
20155989
13.

The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study.

El-Serag HB, Fitzgerald S, Richardson P.

Am J Gastroenterol. 2009 Sep;104(9):2161-7. doi: 10.1038/ajg.2009.312. Epub 2009 Jun 30.

PMID:
19568229
14.

Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.

Higginbotham TW.

Ann Pharmacother. 2010 Mar;44(3):572-6. doi: 10.1345/aph.1M519. Epub 2010 Feb 2. Review.

PMID:
20124466
15.

Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study.

Kim KM, Cho YK, Bae SJ, Kim DS, Shim KN, Kim JH, Jung SW, Kim N.

J Gastroenterol Hepatol. 2012 Apr;27(4):741-5. doi: 10.1111/j.1440-1746.2011.06921.x.

PMID:
21916988
16.

Disease-specific cost savings of treating nighttime versus daytime gastroesophageal reflux disease in an employed population.

Doan QV, Lange SM, Elfant A, Aguilar D, Reyes E, Lynn RB, Dubois RW.

J Med Econ. 2008;11(1):23-40. doi: 10.3111/13696990701815545.

PMID:
19450108
17.

Non-cardiac chest pain: the long-term natural history and comparison with gastroesophageal reflux disease.

Williams JF, Sontag SJ, Schnell T, Leya J.

Am J Gastroenterol. 2009 Sep;104(9):2145-52. doi: 10.1038/ajg.2009.279. Epub 2009 Jun 9.

PMID:
19513020
18.

Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected].

Heidelbaugh JJ, Goldberg KL, Inadomi JM.

Am J Gastroenterol. 2009 Mar;104 Suppl 2:S27-32. doi: 10.1038/ajg.2009.49. Review. Erratum in: Am J Gastroenterol. 2009 Apr;104(4):1072. Am J Gastroenterol. 2009 Mar;104(2 Suppl):S39.

PMID:
19262544
19.

Gastroesophageal reflux disease (GERD): is there more to the story?

Vesper BJ, Altman KW, Elseth KM, Haines GK 3rd, Pavlova SI, Tao L, Tarjan G, Radosevich JA.

ChemMedChem. 2008 Apr;3(4):552-9. Review.

PMID:
18076011
20.

The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.

Gosselin A, Luo R, Lohoues H, Toy E, Lewis B, Crawley J, Duh MS.

Value Health. 2009 Jan-Feb;12(1):34-9. doi: 10.1111/j.1524-4733.2008.00399.x. Epub 2008 Jul 15.

Supplemental Content

Support Center